Klinik für Dermatologie, Allergologie und Venerologie der Universität zu Lübeck: Interaktion von Forschung und klinischer Versorgung

Zusammenfassung

Die Ursprünge der Lübecker Universitäts-Hautklinik reichen in die 30er-Jahre des letzten Jahrhunderts zurück. Die Klinik hat in den letzten Jahrzehnten eine konsequente bauliche und inhaltliche Weiterentwicklung erfahren und verfügt heute über 85 Betten auf 2 Stationen und in einer Tagesklinik. Ein modernes Weiterbildungsprogramm, das auf einem Rotationsprinzip durch 5 verschiedene stationäre und ambulante Teams beruht, vermittelt alle wesentlichen Lerninhalte der Dermatologie. Die Erweiterung der Klinik in den letzten Jahren beruhte auf einer engen Interaktion von Grundlagenforschung und klinischer Tätigkeit, insbesondere auf dem Gebiet kutaner Autoimmunerkrankungen und entzündlicher Dermatosen. Die wissenschaftliche Entwicklung der Hautklinik profitierte seit 2007 insbesondere von der Förderung durch die Exzellenzinitiative des Bundes (Exzellenzcluster Inflammation at Interfaces). Daneben wurde durch die Deutsche Forschungsgemeinschaft (DFG) seit 2011 unter Federführung der Hautklinik ein Graduiertenkolleg Modulation of Autoimmunity gefördert, das zur Entwicklung des wissenschaftlichen Nachwuchses und zur Ausbildung zahlreicher naturwissenschaftlicher und medizinischer Doktoranden/Doktorandinnen[1] beitrug. Seit 2015 besteht an der Klinik auch eine Klinische Forschungsgruppe der DFG zum Thema Pemphigoid Diseases – Molecular Pathways and their Therapeutic Potential. Im Jahr 2018 haben Mitarbeiter der Klinik wesentlich zur Einwerbung eines Clinician Scientist-Programms der DFG beigetragen, das die wissenschaftliche Ausbildung forschender Kliniker verbessern soll. In den letzten Jahren haben sich aus der Lübecker Hautklinik heraus 2 eigenständige Institute neu etabliert. Hierzu zählen das Institut für Entzündungsmedizin unter der Leitung von Prof. Diamant Thaçi, in dem klinische Studien zu entzündlichen Hauterkrankungen initiiert und koordiniert werden und die Versorgung von Patienten mit entzündlichen Dermatosen stattfindet. Daneben ist aus der Hautklinik heraus das Lübecker Institut für Experimentelle Dermatologie (LIED) entstanden, in dem derzeit 5 Professoren mit ihren jeweiligen Arbeitsgruppen zu unterschiedlichen Themen der Entzündung an der Haut forschen. Die interdisziplinären wissenschaftlichen Aktivitäten zur Entzündung an der Haut am Lübecker Campus werden seit 2015 in einem Center for Research on Inflammation of the Skin (CRIS) gebündelt. CRIS erhielt kürzlich die Zusage für ein eigenständiges Forschungsgebäude, das nach § 91 Grundgesetz durch Bund und Land finanziert wird und derzeit im Zentrum des Lübecker Campus entsteht. Der Ausbau der Forschungsstrukturen der Klinik ging mit der Einrichtung von Spezialambulanzen für verschiedene entzündliche Hauterkrankungen, aber auch für die Versorgung von Hautkrebs und chronischen Wunden einher. Die Klinik verfügt über ein zertifiziertes Hautkrebszentrum und ist Teil der Lübecker universitären Gefäß- und Krebszentren. Weitere wichtige Pfeiler der klinischen Versorgung sind zertifizierte diagnostische Einsendelabore für Dermato-Histopathologie und kutane Autoimmunerkrankungen.

Abstract

The origins of the Lübeck University Department of Dermatology date back to the 30s of the last century. Over the past few decades, the department has undergone consistent structural development and today has 85 beds on two wards and a day-care clinic. A modern residency training program, based on rotations between 5 different inpatient and outpatient teams, conveys all essential topics of clinical dermatology. The extension of the department in recent years has been based on a close interaction of basic research and clinical activities, in particular in the field of cutaneous autoimmune and inflammatory diseases. Since 2007, the scientific development of the department has benefited in particular from funding by the Federal Excellence Initiative (Cluster of Excellence Inflammation at Interfaces). In addition, the German Research Foundation (DFG) has been funding a Research Training Group Modulation of Autoimmunity since 2011 under the auspices of the Dermatology Department. This greatly contributed to the development of young scientists and to the training of numerous PhD and MD students. Since 2015, several scientists of the Department have been funded through a DFG Clinical Research Group entitled Pemphigoid Diseases – Molecular Pathways and their Therapeutic Potential. In 2018, researchers of the department also contributed to the acquisition of a Clinician Scientist program of the DFG, which aims to improve the basic scientific training of clinicians. In recent years, as a spin-off from the Dermatology Department, two additional and independent institutes have been established. These include the Institute of Inflammation Medicine, led by Prof. Diamant Thaçi, which initiates and coordinates clinical trials on inflammatory skin diseases and provides care to patients with inflammatory dermatoses. In addition, the Lübeck Institute for Experimental Dermatology (LIED) has emerged from the Department of Dermatology, in which currently 5 professors with their respective research groups work on different topics of inflammation on the skin. Since 2015, the interdisciplinary scientific activities on skin inflammation on the Lübeck campus have been bundled in a Center for Research on Inflammation of the Skin (CRIS). CRIS recently received a commitment for an independent research building, which is funded by both the Federal Government and the State of Schleswig-Holstein in accordance with § 91 of the German constitution, and is currently being built in the center of the Lübeck campus. The expansion of the department’s research structures has been accompanied by the establishment of special outpatient clinics for various inflammatory skin diseases, but also for the treatment of skin cancer and chronic wounds. The department has been certified as a Skin Cancer Center and is part of the Lübeck University Vascular and Cancer Centers. Other important pillars of the department’s clinical care include certified diagnostic laboratories for dermatopathology and cutaneous autoimmune diseases.

¹ Im Folgenden wird zur besseren Lesbarkeit nur die männliche Form verwendet. Diese schließt aber jeweils auch die weibliche Form mit ein.

Publikationsverlauf

Publikationsdatum:
10. Februar 2020 (online)

• Literatur

• 1 Wolf HH, Zillikens D. Klinik für Dermatologie und Venerologie. Focus MUL 2004; 21: 230-232
• 2 von Detmering WD. Vom Krankenhaus Ost zur Schwerpunktuniversität Lübeck. Fokus MUL 2004; 21: 138-143
• 3 Lüttmann N, Grätz V, Haase O. et al. Rapid remission of symptomatic brain metastases in melanoma by programmed-death-receptor-1 inhibition. Melanoma Res 2016; 26: 528-531
• 4 Anemüller W, Recke A, Altgassen C. et al. Aufbau einer interdisziplinären Vulvasprechstunde. J Dtsch Dermatol Ges 2012; 10: 350-357
• 5 Recke A, Recke AL, Jappe U. Periorbital contact dermatitis caused by octylisothiazolinone in a floor-cleaning agent. Contact Dermatitis 2015; 72: 339-341
• 6 Schmidt E, Zillikens D. The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int 2011; 108: 399-405
• 7 Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332
• 8 Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet 2019; 394: 882-894
• 9 Kasperkiewicz M, Ellebrecht C, Takahashi H. et al. Pemphigus. Nat Rev Dis Primers 2017; 3: 17026
• 10 Schmidt E, Groves R. Immunobullous diseases. In: Griffiths C, Barker J, Bleiker T. et al., eds. Rookʼs Textbook of Dermatology. Part 3, Chapter 50. 9th. ed. Chichester: Wiley-Blackwell; 2016: 1-56
• 11 Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 2011; 29: 427-438
• 12 Sticherling M, Franke A, Aberer E. et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol 2017; 177: 1299-1305
• 13 Williams HC, Wojnarowska F, Kirtschig G. et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 2017; 389: 1630-1638
• 14 van Beek N, Knuth-Rehr D, Altmeyer P. et al. Diagnostics of autoimmune bullous diseases in German dermatology departments. J Dtsch Dermatol Ges 2012; 10: 492-499
• 15 Schmidt E, Goebeler M, Hertl M. et al. S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 2015; 13: 713-727
• 16 van Beek N, Zillikens D, Schmidt E. Diagnosis of autoimmune bullous diseases. J Dtsch Dermatol Ges 2018; 16: 1077-1091
• 17 Meijer JM, Atefi I, Diercks GFH. et al. Serration pattern analysis for differentiating epidermolysis bullosa acquisita from other pemphigoid diseases. J Am Acad Dermatol 2018; 78: 754-759 e6
• 18 Blöcker IM, Dahnrich C, Probst C. et al. Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid. Br J Dermatol 2012; 166: 964-970
• 19 Probst C, Schlumberger W, Stocker W. et al. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta 2009; 410: 13-18
• 20 Schmidt E, Dahnrich C, Rosemann A. et al. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol 2010; 19: 458-463
• 21 Sitaru C, Dahnrich C, Probst C. et al. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007; 16: 770-777
• 22 van Beek N, Dahnrich C, Johannsen N. et al. Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases. J Am Acad Dermatol 2017; 76: 889-894 e5
• 23 Komorowski L, Muller R, Vorobyev A. et al. Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. J Am Acad Dermatol 2012; 68: e89-95
• 24 van Beek N, Rentzsch K, Probst C. et al. Serological diagnosis of autoimmune bullous skin diseases: Prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis 2012; 7: 49
• 25 Goletz S, Probst C, Komorowski L. et al. A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid. Br J Dermatol 2019; 180: 149-156
• 26 Mindorf S, Dettmann IM, Kruger S. et al. Routine detection of serum antidesmocollin autoantibodies is only useful in patients with atypical pemphigus. Exp Dermatol 2017; 26: 1267-1270
• 27 Thaçi D, Simpson EL, Beck LA. et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016; 387: 40-52
• 28 Beck LA, Thaçi D, Hamilton JD. et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371: 130-139
• 29 Papp K, Thaçi D, Marcoux D. et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet 2017; 390: 40-49
• 30 Papp K, Gordon K, Thaçi D. et al. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med 2018; 379: 1313-1321
• 31 Klett H, Jurgensen L, Most P. et al. Delineating the dynamic transcriptome response of mRNA and microRNA during zebrafish heart regeneration. Biomolecules 2018; DOI: 10.3390/biom9010011.
• 32 Hirose M, Schilf P, Gupta Y. et al. Low-level mitochondrial heteroplasmy modulates DNA replication, glucose metabolism and lifespan in mice. Sci Rep 2018; 8: 5872
• 33 Staats S, Wagner AE, Luersen K. et al. Dietary ursolic acid improves health span and life span in male Drosophila melanogaster. BioFactors 2019; 45: 169-186
• 34 Pastor VB, Sahoo SS, Boklan J. et al. Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7. Haematologica 2018; 103: 427-437
• 35 He Y, Maier K, Leppert J. et al. Monoallelic Mutations in the Translation Initiation Codon of KLHL24 Cause Skin Fragility. Am J Hum Genet 2016; 99: 1395-1404
• 36 Elghzaly AA, Metwally SS, El-Chennawi FA. et al. IRF5, PTPN22, CD28, IL2RA, KIF5A, BLK and TNFAIP3 genes polymorphisms and lupus susceptibility in a cohort from the Egypt Delta; relation to other ethnic groups. Hum Immunol 2015; 76: 525-531
• 37 Ludwig RJ, Muller S, Marques A. et al. Identification of quantitative trait loci in experimental epidermolysis bullosa acquisita. J Invest Dermatol 2012; 132: 1409-1415
• 38 Srinivas G, Moller S, Wang J. et al. Genome-wide mapping of gene-microbiota interactions in susceptibility to autoimmune skin blistering. Nat Commun 2013; 4: 2462
• 39 Hirose M, Schilf P, Benoit S. et al. Polymorphisms in the mitochondrially encoded ATP synthase 8 gene are associated with susceptibility to bullous pemphigoid in the German population. Exp Dermatol 2015; 24: 715-717
• 40 Hirose M, Schilf P, Gupta Y. et al. Lifespan effects of mitochondrial mutations. Nature 2016; 540: E13-E14
• 41 Yu X, Gimsa U, Wester-Rosenlof L. et al. Dissecting the effects of mtDNA variations on complex traits using mouse conplastic strains. Genome Res 2009; 19: 159-165
• 42 Sitaru C, Mihai S, Otto C. et al. Induction of dermal-epidermal separation in mice by passive transfer of antibodies to type VII collagen. J Clin Invest 2005; 115: 870-878
• 43 Karsten CM, Pandey MK, Figge J. et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med 2012; 18: 1401-1406
• 44 Koga H, Recke A, Vidarsson G. et al. PDE4 inhibition as potential treatment of epidermolysis bullosa acquisita. J Invest Dermatol 2016; 136: 2211-2220
• 45 Burmester IAK, Emtenani S, Johns JG. et al. Translational Use of a Standardized Full Human Skin Organ Culture Model in Autoimmune Blistering Diseases. Curr Protoc Pharmacol 2019; 85: e56
• 46 Kasprick A, Bieber K, Ludwig RJ. Drug Discovery for Pemphigoid Diseases. Curr Protoc Pharmacol 2019; 84: e55
• 47 Vorobyev A, Gupta Y, Sezin T. et al. Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line. Nat Commun 2019; DOI: 10.1038/s41467-019-11952-w.
• 48 van Beek N, Dahnrich C, Johannsen N. et al. Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases. J Am Acad Dermatol 2017; 76: 889-894 e5
• 49 van Beek N, Luttmann N, Huebner F. et al. Correlation of serum levels of IgE autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity. JAMA Dermatol 2017; 153: 30-38
• 50 Heppe EN, Tofern S, Schulze FS. et al. Experimental Laminin 332 Mucous Membrane Pemphigoid Critically Involves C5aR1 and Reflects Clinical and Immunopathological Characteristics of the Human Disease. J Invest Dermatol 2017; 137: 1709-1718
• 51 Chakievska L, Holtsche MM, Kunstner A. et al. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun 2019; 96: 104-112